Literature DB >> 12558956

Cytokine profile and supposed contribution to scarring in cicatricial pemphigoid.

Marzia Caproni1, Anna Calzolari, Elisabetta Salvatore, Barbara Giomi, Walter Volpi, Alberino D'Agata, Marco Santucci, Paolo Fabbri.   

Abstract

BACKGROUND: The progressive scarring observed in cicatricial pemphigoid (CP) is still partially unexplained but recently the release of soluble fibrogenic factors by inflammatory infiltrating cells has been considered as pathogenically relevant. In the present study we evaluated the expression of mRNA for IL-4, IL-5, TGF-beta1, IFN-gamma in CP in comparison to bullous pemphigoid (BP) patients, investigating the role of cytokine profile as possible cause of the different disease evolution.
METHODS: Biopsies from patients with oral (n = 10), preputial (n = 3) and cutaneous (n = 1) CP were studied by in situ hybridisation performing a new amplification system based on biotinyl-tyramide. As control, four patients affected by BP were also examined, together with healthy tissue from two CP and two BP patients, respectively.
RESULTS: In CP IL-4 mRNA expression was present in 4 out of 14 cases analysed. IL-5 was detected in 12 CP biopsies. TGF-beta1 and IFN-gamma mRNAs were identified in 9 and 11 CP cases, respectively. In BP, IL-4 hybridisation signal could not be observed in any of the cases. By contrast IL-5, TGF-beta1 and IFN-gamma mRNA analyses were positive in all BP cases. Healthy specimens did not show any expression for IL-4, IL-5 and IFN-gamma, while a poor staining for TGF-beta was found in epithelium and subjunctional areas.
CONCLUSIONS: Our results highlight the presence of a mixed cytokine pattern in the cellular infiltrate of both blistering diseases, with a corresponding increase of Th2-like activity in fully developed lesions, irrespective of the different sites involved. In addition, the constant presence of TGF-beta1 mRNA in the different lesional phases of CP, and its overlapping expression in BP suggest that the involvement of additional factors is responsible for the scarring course typical of CP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558956     DOI: 10.1034/j.1600-0714.2003.00028.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

1.  [Topical immunomodulators: a therapeutic option for oral cicatricial pemphigoid].

Authors:  T Assmann; T Burchardt; J Becker; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

Review 2.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

3.  Limbal Fibroblasts Maintain Normal Phenotype in 3D RAFT Tissue Equivalents Suggesting Potential for Safe Clinical Use in Treatment of Ocular Surface Failure.

Authors:  Isobel Massie; Sarah B Dale; Julie T Daniels
Journal:  Tissue Eng Part C Methods       Date:  2014-12-17       Impact factor: 3.056

4.  Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.

Authors:  Sarah D Ahadome; David J Abraham; Suryanarayana Rayapureddi; Valerie P Saw; Daniel R Saban; Virginia L Calder; Jill T Norman; Markella Ponticos; Julie T Daniels; John K Dart
Journal:  JCI Insight       Date:  2016-08-04

5.  Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Authors:  Amy Attaway; Tracey L Mersfelder; Sakshi Vaishnav; Joanne K Baker
Journal:  J Dermatol Case Rep       Date:  2014-03-31

6.  Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro.

Authors:  Valerie P J Saw; Ifeoma Offiah; Robin J Dart; Grazyna Galatowicz; John K G Dart; Julie T Daniels; Virginia L Calder
Journal:  Am J Pathol       Date:  2009-11-12       Impact factor: 4.307

7.  Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.

Authors:  Olivier Gaudin; Vannina Seta; Marina Alexandre; Gérôme Bohelay; Françoise Aucouturier; Sabine Mignot-Grootenboer; Saskia Ingen-Housz-Oro; Céline Bernardeschi; Pierre Schneider; Benoît Mellottee; Frédéric Caux; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2018-05-24       Impact factor: 7.561

Review 8.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.